News Releases
by Year
2011
Dec. 05, 2011 (PDF/153KB) R&D
STEDESA™ clinical data presented at 2011 American Epilepsy Society Annual Meeting
Dec. 01, 2011 (PDF/25KB) Products
Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN and LULLAN
Nov. 30, 2011 (PDF/43KB) R&D
Dainippon Sumitomo Pharma announces application for manufacturing and marketing approval for "DSP-8153", combination product of irbesartan and amlodipine besilate
Nov. 28, 2011 (PDF/90KB) Products
Dainippon Sumitomo Pharma announces the launch of Alzheimer's Disease Treatment Donepezil hydrochloride tablets/OD tablets 3mg/5mg "DSP"
Oct. 31, 2011 (PDF/283KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2012
Oct. 31, 2011 (PDF/169KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2012 (Unaudited)
Oct. 31, 2011 (PDF/73KB) Finances
Difference from Financial Forecasts for the Second Quarter of the Year Ending March 31, 2012 and Revision of Financial Forecasts for the Year Ending March 31, 2012
Oct. 27, 2011 (PDF/102KB) R&D
LATUDA (lurasidone HCl) Shown to be Non-Inferior to SEROQUEL XR (quetiapine fumarate XR) in Risk for Relapse in a 12-Month, Double-Blind Extension Study of Adult Patients with Schizophrenia
Sep. 02, 2011 (PDF/95KB) Finances
Dainippon Sumitomo Pharma Co., Ltd. Announces Issuance of Unsecured Straight Bonds
Aug. 24, 2011 (PDF/35KB) R&D
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia
Jul. 29, 2011 (PDF/444KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2012
Jul. 29, 2011 (PDF/163KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2012 (Unaudited)
Jul. 19, 2011 (PDF/103KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Alzheimer's Disease Treatment "Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]".
Jun. 07, 2011 (PDF/60KB) R&D
Collaborative Research on Apoptosis Inhibitor of Macrophages (AIM)
Jun. 07, 2011 (PDF/55KB) R&D
Sunovion Announces FDA Acceptance of New Drug Application for Ciclesonide HFA Nasal Aerosol
Jun. 01, 2011 (PDF/50KB) R&D
Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue
May 11, 2011 (PDF/122KB) R&D
Results of a Phase II Clinical Trial for Ranirestat - Therapeutic Agent for Diabetic Complications
May 11, 2011 (PDF/53KB) Corporate
Change of Members of Board of Directors, Corporate Auditors and Executive Officers
May 11, 2011 (PDF/120KB) R&D
Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia
May 11, 2011 (PDF/51KB) Corporate
Change of Representative Directors
May 11, 2011 (PDF/413KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2011 (Unaudited)
May 11, 2011 (PDF/402KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2011
May 09, 2011 (PDF/81KB) Products
Dainippon Sumitomo Pharma announces the launch of SUREPOST, a rapid-acting insulin secretagogue
Apr. 27, 2011 (PDF/25KB) Licensing
Dainippon Sumitomo Pharma and Maruho Enter into a License Agreement for a Novel Topical Analgesic Drug
Apr. 25, 2011 (PDF/115KB) R&D
CiRA and DSP Research the Creation of a New Treatment for Rare Intractable Diseases
Apr. 07, 2011 (PDF/25KB) Licensing
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
Apr. 05, 2011 (PDF/125KB) Finances
Impact of the Great East Japan Earthquake (Part 2)
Mar. 31, 2011 (PDF/58KB) Sustainability
Dainippon Sumitomo Pharma Group Contributes to Earthquake Relief Efforts in Japan (Part 2)
Mar. 30, 2011 (PDF/65KB) Finances
Revision of Financial Forecasts for the Year Ending March 31, 2011
Mar. 30, 2011 (PDF/26KB) Licensing
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
Mar. 30, 2011 (PDF/130KB) Licensing
Takeda and DSP Sign Development, Manufacturing and Commercialization Agreement for a Cephem Antibiotic Ceftaroline in Japan
Mar. 30, 2011 (PDF/199KB) Licensing
DSP and Takeda Sign Development and Commercialization Agreement for an Atypical Antipsychotic Agent Lurasidone in Europe
Mar. 17, 2011 (PDF/78KB) Sustainability
Dainippon Sumitomo Pharma Group Contributes to Earthquake Relief Efforts in Japan
Mar. 17, 2011 (PDF/139KB) Finances
Impact of the Tohoku Earthquake
Mar. 15, 2011 (PDF/37KB) R&D
Laboratory for Malignancy Control Research
Mar. 15, 2011 (PDF/56KB) Sustainability
Dainippon Sumitomo Pharma Contributes to Earthquake Relief Efforts in Japan
Mar. 10, 2011 (PDF/79KB) Products
Approval obtained for partial change in dosage and administration of MEROPEN, a carbapenem antibiotic preparation
Mar. 02, 2011 (PDF/95KB) Finances
Dainippon Sumitomo Pharma Co., Ltd. Announces Issuance of Unsecured Straight Bonds
Mar. 01, 2011 (PDF/52KB) Corporate
Execution of the definitive agreement for the assignment of "Radarcirc" business
Feb. 03, 2011 (PDF/47KB) Products
Dainippon Sumitomo Pharma Co. Ltd. (DSP) Announces Launch of Latuda (lurasidone HCl) in the United States
Feb. 03, 2011 (PDF/300KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2011 (Unaudited)
Feb. 03, 2011 (PDF/258KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2011
Feb. 03, 2011 (PDF/60KB) Finances
Revision of Financial Forecasts for the Fiscal Year Ending March 31, 2011
Jan. 25, 2011 (PDF/50KB) R&D
Completion of Long-Term Phase 3 Safety Trial for Latuda (lurasidone HCl)
Jan. 21, 2011 (PDF/51KB) Products
SUREPOST, a rapid-acting insulin secretagogue, obtains a manufacturing and marketing approval